Inventor · disambiguated record
Jens Fischer
Also filed as: FISCHER JENS
18 granted patents·24 pending applications·127 citations·filing 2011–2025
93Inventor score
Top patents by PatentIndex Score
42 records- 0195US9346872B2Interleukin-10 fusion proteinsROCHE GLYCART AG·Filed 2013·Granted May 24, 2016·43 cites·22 claims
- 0293US11285207B2Bispecific antibodies specifically binding to PD1 and LAG3HOFFMANN LA ROCHE·Filed 2018·Granted Mar 29, 2022·10 cites·32 claims
- 0392US10718762B2Cellular based fret assay for the determination of simultaneous bindingHOFFMANN LA ROCHE·Filed 2018·Granted Jul 21, 2020·5 cites·8 claims
- 0491US9714292B2Bispecific antibodies against human TWEAK and human IL17 and uses thereofHOFFMANN LA ROCHE·Filed 2014·Granted Jul 25, 2017·21 cites·14 claims
- 0590US10287352B2Bispecific antibodies specific for PD1 and TIM3HOFFMANN LA ROCHE·Filed 2016·Granted May 14, 2019·10 cites·21 claims
- 0689US11130810B2Bispecific antibodies specific for PD1 and TIM3HOFFMANN LA ROCHE·Filed 2019·Granted Sep 28, 2021·4 cites·36 claims
- 0788US10040843B2Interleukin-10 fusion proteins and uses thereofROCHE GLYCART AG·Filed 2016·Granted Aug 7, 2018·7 cites·22 claims
- 0887US10434184B2Anti-TPBG antibodies and methods of useHOFFMANN LA ROCHE·Filed 2018·Granted Oct 8, 2019·3 cites·22 claims
- 0986US9309319B2Antibodies against human IL33R and uses thereofHOFFMANN LA ROCHE·Filed 2014·Granted Apr 12, 2016·8 cites·7 claims
- 1083US8883975B2Antibodies against IL-18R1 and uses thereofBRANDT MICHAEL·Filed 2011·Granted Nov 11, 2014·14 cites·22 claims
- 1183US2024294642A1Anti-pd1 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1282US11739142B2Bispecific anti-CCL2 antibodiesHOFFMANN LA ROCHE·Filed 2020·Granted Aug 29, 2023·1 cites·2 claims
- 1381US2023183349A1Anti-pd1 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1479US2025051456A1Anti-hla-g antibodies and methods of use thereofHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 1578US2023143310A1Anti-pd1 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 1678US2025313629A1Anti-lag3 antibodiesHOFFMANN LA ROCHE·Filed 2025·Application pending·0 cites
- 1777US12103967B2Bispecific anti-CCL2 antibodiesHOFFMANN LA ROCHE·Filed 2023·Granted Oct 1, 2024·0 cites·27 claims
- 1876US2024002506A1Anti-lag3 antibodiesHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1975US2023399396A1Cd40l expressing mammalian cells and their useHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 2072US2024083993A1Bispecific anti-ccl2 antibodiesHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 2171US2025051455A1Multispecific antibodies and use thereofHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 2270US12391757B2Bispecific antibodies specific for PD1 and TIM3HOFFMANN LA ROCHE·Filed 2021·Granted Aug 19, 2025·0 cites·20 claims
- 2369US10329346B2TNFa-IL-17 bispecific antibodiesHOFFMANN LA ROCHE·Filed 2016·Granted Jun 25, 2019·1 cites·23 claims
- 2467US2022211865A1Reduction of application-related side reaction of a therapeutic antibodyHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 2566US2022387586A1Bispecific antibodies specifically binding to pd1 and lag3HOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 2664US12157770B2Anti-HLA-G antibodies and methods of use thereofHOFFMANN LA ROCHE·Filed 2020·Granted Dec 3, 2024·0 cites·11 claims
- 2763US2019153091A1Cd40l expressing mammalian cells and their useHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 2863US2020277372A1Anti-lag3 antibodiesHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 2962US2019382489A1Anti-pd1 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 3061US12258371B2Stabilized immunoglobulin domainsHOFFMANN LA ROCHE·Filed 2020·Granted Mar 25, 2025·0 cites·10 claims
- 3159US11981737B2Anti-HLA-G antibodies and use thereofHOFFMANN LA ROCHE·Filed 2019·Granted May 14, 2024·0 cites·9 claims
- 3259US2018344869A1Reduction of application-related side reaction of a therapeutic antibodyHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 3358US2020289665A1Reduction of application-related side reaction of a therapeutic antibodyHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3458US2024360208A1Bispecific anti-ccl2 antibodiesHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 3558US2014315252A1Cd40l expressing mammalian cells and their useHOFFMANN LA ROCHE·Filed 2012·Application pending·0 cites
- 3656US2022098305A1Novel icos antibodies and tumor-targeted antigen binding molecules comprising themHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 3756US2017247454A1Anti-pd1 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 3856US2021147554A1Multispecific antibodies and use thereofHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3953US8785153B2Antibodies against human IL33R and uses thereofFERTIG GEORG·Filed 2012·Granted Jul 22, 2014·0 cites·16 claims
- 4053US2023340081A1Anti-hbv antibodies and methods of useHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 4146US2020354457A1Bispecific antibodies comprising an antigen-binding site binding to lag3HOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 4233US2015218244A1Interleukin-10 fusion proteins and uses thereofHOFFMANN LA ROCHE·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jens Fischer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →